Peer into your child’s future – medically, not astrologically!


I’ve been following noninvasive prenatal testing (NIPT) technology very closely, as QIAGEN is becoming a pioneer in providing solutions for liquid biopsy-based research. Liquid biopsy is considered by many to have great potential in the future for predictive diagnostics. Recently, I came across an interesting news article on CNN Frontiers, focusing on the scientist who first discovered fetal DNA in the mother’s plasma in autumn of 1996. While his groundbreaking discovery didn’t receive much attention at the time, Dr. Dennis Lo’s work has been turning a lot of heads in the last few years. To read his interview with CNN, go to this link at the CNN website.

Prenatal diagnosis with fetal cell-free DNA circulating in the mother’s blood opens up a multitude of possibilities, from predicting diseases to eye color to cancer. You can learn more about cell-free DNA (cfDNA) and best practices for studying circulating cfDNA in liquid biopsy research at our webinar series. Check it out!

Abhishek Sharma, Msc., MBA

Senior Global Market Manager, Discovery Sciences

Abhishek Sharma trained as a biochemist and has hands-on experience in nucleic acid and protein purification, tissue culturing and recombinant DNA technology. Previously, he was as a market analyst on emerging technologies in life science research. Sharma also worked in a USA-based healthcare consultancy on the discovery, development and commercialization of new disease treatments across multiple therapeutic areas. Currently, he’s involved with managing QIAGEN’s sample preparation portfolio, specializing in RNA technologies.

Your email address will not be published. Required fields are marked *